Ba253BINEB in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A Phase III Long-term Study of Ba253BINEB in Patients With COPD
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
The patients with COPD (chronic bronchitis, emphysema) and who satisfy the following criteria
- Patients with FEV1.0/FVC (Forced vital capacity) of <= 70% in the screening test and whose symptoms are stable
- Patients aged >= 40 years or older
- Patients must be able to understand the patient information form
Exclusion Criteria:
- Patients complicated with bronchial asthma, making the assessment of drug efficacy against COPD difficult
- Patients who have taken an long acting corticosteroids(i.m.) within 1 month before the study
- Patients using oral corticosteroid medication at a dose in excess of the equivalent 5 mg/day of prednisolone
- Patients with glaucoma
- Patients who have prostatic hypertrophy
- Patients with hypersensitivity to anticholinergic drugs
- Patients with serious hepatic disease, kidney disease or heart disorder and who are judged by the investigator as inappropriate as the subjects of study
- Women who are pregnant or who may become pregnant, or nursing women
- Patients who are judged by the investigator as inappropriate as the subjects of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Ba253BINEB
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Patients with Adverse Events
Time Frame: Up to 28 weeks
|
Up to 28 weeks
|
|
Number of patients with significant changes from baseline in vital signs (blood pressure, heart rate)
Time Frame: Baseline, up to week 28
|
Baseline, up to week 28
|
|
Number of patients with abnormal changes from baseline in electrocardiogram (ECG)
Time Frame: Baseline, up to week 28
|
Baseline, up to week 28
|
|
Number of patients wiht abnormal changes from baseline in laboratory tests
Time Frame: Baseline, up to week 28
|
Baseline, up to week 28
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from baseline in FEV1 (Forced expiratory volume in one second)
Time Frame: Baseline, up to week 28
|
Baseline, up to week 28
|
|
Change from baseline in COPD symptom scoring (cough, sputum amount, shortness of breath, nocturnal sleep)
Time Frame: Baseline, up to week 28
|
Baseline, up to week 28
|
|
Physician's global evaluation (overall improvement)
Time Frame: Up to week 28
|
Up to week 28
|
|
Patient's impression
Time Frame: Week 28
|
Week 28
|
|
Physician's global evaluation (final improvement)
Time Frame: Week 28
|
Week 28
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 54.561
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.